FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891753617> ?p ?o ?g. }

• W2891753617 abstract "To date, the clinical benefit of topical steroid use has only been demonstrated for radiation dermatitis induced by 50-60 Gy irradiation in breast cancer. However, these agents are also often used clinically for the control of radiation dermatitis induced by high-dose (>60Gy) irradiation with chemotherapy in head and neck cancer. Despite this, the prophylactic efficacy of topical steroids for radiation dermatitis induced by high-dose irradiation is still unclear. The aim of this study is to clarify the benefit of topical steroids in basic nursing care for radiation dermatitis induced by chemoradiotherapy in patients with head and neck cancer.The study is being conducted as a multicenter 2-arm randomized double-blinded placebo-controlled Phase 3 trial in Japan. The study was started in May 2017, with participant enrollment between May 2017 and April 2019. Patients scheduled to receive definitive or postoperative chemoradiotherapy for head and neck cancer are eligible for enrollment. All patients will receive chemoradiotherapy, consisting of single agent CDDP and 70-Gy irradiation. Bilateral neck irradiation is mandatory. Supportive care for radiation dermatitis will consist of basic nursing care with topical steroid or placebo. When radiation dermatitis grade 1 is seen or total radiation dose reaches 30 Gy, minimally required intervention will be started as a first step. If radiation dermatitis worsens to grade 2, the irradiated area will be covered with a moderately absorbent surgical pad and steroid or placebo topical cream. The primary endpoint is a comparison of the proportion of patients with ≥ grade 2 radiation dermatitis by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Ethical approval has been obtained from all participating sites. The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at international scientific conferences.Evidence supporting the benefit of adding topical steroids in general nursing care for radiation dermatitis induced by high-dose irradiation with chemotherapy is insufficient. This trial aims to clarify the clinical benefit of topical steroid for radiation dermatitis induced by high-dose irradiation with chemotherapy. The trial is ongoing and is currently recruiting.UMIN000027161 . Protocol version 3.0, 18 April 2017." @default.
• W2891753617 created "2018-09-27" @default.
• W2891753617 creator A5000636193 @default.
• W2891753617 creator A5004493549 @default.
• W2891753617 creator A5039570247 @default.
• W2891753617 creator A5048326346 @default.
• W2891753617 creator A5049820100 @default.
• W2891753617 creator A5060867222 @default.
• W2891753617 creator A5061893367 @default.
• W2891753617 creator A5062835253 @default.
• W2891753617 creator A5066930732 @default.
• W2891753617 creator A5068369923 @default.
• W2891753617 creator A5069218384 @default.
• W2891753617 creator A5071947905 @default.
• W2891753617 creator A5074986035 @default.
• W2891753617 creator A5079504645 @default.
• W2891753617 creator A5079987281 @default.
• W2891753617 date "2018-09-06" @default.
• W2891753617 modified "2023-10-14" @default.
• W2891753617 title "Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial" @default.
• W2891753617 cites W1986371466 @default.
• W2891753617 cites W1989991364 @default.
• W2891753617 cites W2015649106 @default.
• W2891753617 cites W2020794572 @default.
• W2891753617 cites W2027616625 @default.
• W2891753617 cites W2036005555 @default.
• W2891753617 cites W2040911364 @default.
• W2891753617 cites W2085488843 @default.
• W2891753617 cites W2092376192 @default.
• W2891753617 cites W2093274439 @default.
• W2891753617 cites W2095029943 @default.
• W2891753617 cites W2100961085 @default.
• W2891753617 cites W2120068217 @default.
• W2891753617 cites W2142222095 @default.
• W2891753617 cites W2145078756 @default.
• W2891753617 cites W2156298938 @default.
• W2891753617 cites W2303213193 @default.
• W2891753617 doi "https://doi.org/10.1186/s12885-018-4763-1" @default.
• W2891753617 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6127935" @default.
• W2891753617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30189840" @default.
• W2891753617 hasPublicationYear "2018" @default.
• W2891753617 type Work @default.
• W2891753617 sameAs 2891753617 @default.
• W2891753617 citedByCount "12" @default.
• W2891753617 countsByYear W28917536172019 @default.
• W2891753617 countsByYear W28917536172020 @default.
• W2891753617 countsByYear W28917536172021 @default.
• W2891753617 countsByYear W28917536172022 @default.
• W2891753617 crossrefType "journal-article" @default.
• W2891753617 hasAuthorship W2891753617A5000636193 @default.
• W2891753617 hasAuthorship W2891753617A5004493549 @default.
• W2891753617 hasAuthorship W2891753617A5039570247 @default.
• W2891753617 hasAuthorship W2891753617A5048326346 @default.
• W2891753617 hasAuthorship W2891753617A5049820100 @default.
• W2891753617 hasAuthorship W2891753617A5060867222 @default.
• W2891753617 hasAuthorship W2891753617A5061893367 @default.
• W2891753617 hasAuthorship W2891753617A5062835253 @default.
• W2891753617 hasAuthorship W2891753617A5066930732 @default.
• W2891753617 hasAuthorship W2891753617A5068369923 @default.
• W2891753617 hasAuthorship W2891753617A5069218384 @default.
• W2891753617 hasAuthorship W2891753617A5071947905 @default.
• W2891753617 hasAuthorship W2891753617A5074986035 @default.
• W2891753617 hasAuthorship W2891753617A5079504645 @default.
• W2891753617 hasAuthorship W2891753617A5079987281 @default.
• W2891753617 hasBestOaLocation W28917536171 @default.
• W2891753617 hasConcept C121608353 @default.
• W2891753617 hasConcept C126322002 @default.
• W2891753617 hasConcept C141071460 @default.
• W2891753617 hasConcept C142724271 @default.
• W2891753617 hasConcept C16005928 @default.
• W2891753617 hasConcept C168563851 @default.
• W2891753617 hasConcept C203092338 @default.
• W2891753617 hasConcept C204787440 @default.
• W2891753617 hasConcept C27081682 @default.
• W2891753617 hasConcept C2776530083 @default.
• W2891753617 hasConcept C2778424827 @default.
• W2891753617 hasConcept C509974204 @default.
• W2891753617 hasConcept C530470458 @default.
• W2891753617 hasConcept C71924100 @default.
• W2891753617 hasConceptScore W2891753617C121608353 @default.
• W2891753617 hasConceptScore W2891753617C126322002 @default.
• W2891753617 hasConceptScore W2891753617C141071460 @default.
• W2891753617 hasConceptScore W2891753617C142724271 @default.
• W2891753617 hasConceptScore W2891753617C16005928 @default.
• W2891753617 hasConceptScore W2891753617C168563851 @default.
• W2891753617 hasConceptScore W2891753617C203092338 @default.
• W2891753617 hasConceptScore W2891753617C204787440 @default.
• W2891753617 hasConceptScore W2891753617C27081682 @default.
• W2891753617 hasConceptScore W2891753617C2776530083 @default.
• W2891753617 hasConceptScore W2891753617C2778424827 @default.
• W2891753617 hasConceptScore W2891753617C509974204 @default.
• W2891753617 hasConceptScore W2891753617C530470458 @default.
• W2891753617 hasConceptScore W2891753617C71924100 @default.
• W2891753617 hasIssue "1" @default.
• W2891753617 hasLocation W28917536171 @default.
• W2891753617 hasLocation W28917536172 @default.
• W2891753617 hasLocation W28917536173 @default.
• W2891753617 hasLocation W28917536174 @default.
• W2891753617 hasOpenAccess W2891753617 @default.
• W2891753617 hasPrimaryLocation W28917536171 @default.

• next